Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma
Stopped Lack of efficacy caused enrollment to be stopped at the end of dose escalation
Conditions
- Malignant Rhabdoid Tumors (MRT)
- Neuroblastoma
Interventions
Sponsor
Novartis Pharmaceuticals